|
| ||||||||||
|
|
|
|
|
|
|
||||
| ||||||||||
|
|
|
|
|
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail. Compendium of Animal Rabies Control, 1997 National Association of State Public Health Veterinarians, Inc. *NOTICE This report is being published as a courtesy to both the National Association of State Public Health Veterinarians, Inc., and to the MMWR readership. Its publication does not imply endorsement by CDC. This Compendium provides information on rabies control to veterinarians, public health officials, and others concerned with rabies control. These recommendations serve as the basis for animal rabies-control programs throughout the United States and facilitate standardization of procedures among jurisdictions, thereby contributing to an effective national rabies-control program. This document is reviewed annually and revised as necessary. Recommendations for immunization procedures are contained in Part I; all animal rabies vaccines licensed by the United States Department of Agriculture (USDA) and marketed in the United States are listed in Part II; Part III details the principles of rabies control. Part I: Recommendations for Immunization Procedures
All animal rabies vaccines should be restricted to use by, or under the direct supervision of, a veterinarian. B. Vaccine Selection In comprehensive rabies-control programs, only vaccines with a 3-year duration of immunity should be used. This procedure constitutes the most effective method of increasing the proportion of immunized dogs and cats in any population. (See Part II.) C. Route of Inoculation All vaccines must be administered in accordance with the specifications of the product label or package insert. If administered intramuscularly, it must be at one site in the thigh. D. Vaccination of Wildlife and Hybrids The efficacy of parenteral rabies vaccination of wildlife and hybrids (i.e., the offspring of wild animals crossbred to domestic dogs and cats) has not been established, and no vaccine is licensed for these animals. Zoos or research institutions may establish vaccination programs that attempt to protect valuable animals, but these programs should not replace appropriate public health activities that protect humans. The use of licensed oral vaccines for the mass immunization of free-ranging wildlife should be considered in selected situations, with the approval of the state agency responsible for animal rabies control. E. Accidental Human Exposure to Vaccine Accidental inoculation can occur during administration of animal rabies vaccine. Such exposure to inactivated vaccines constitutes no rabies hazard. F. Identification of Vaccinated Animals All agencies and veterinarians should adopt the standard tag system. This practice will aid the administration of local, state, national, and international rabies-control procedures. Animal license tags should be distinguishable in shape and color from rabies tags. Anodized aluminum rabies tags should be no less than 0.064 inches in thickness.
Part II: Vaccines Marketed in the United States and and NASPHV * Recommendations (Table_1) Part III: Rabies Control
The public should be warned not to handle wildlife. Wild mammals and hybrids that bite or otherwise expose people, pets, or livestock should be considered for euthanasia and rabies examination. A person bitten by any wild mammal should immediately report the incident to a physician who can evaluate the need for antirabies treatment. (See current rabies prophylaxis recommendations of the ACIP.) *
THE NASPHV COMMITTEE: Suzanne R. Jenkins, VMD, MPH, Chair; Keith A. Clark, DVM, PhD; Mira J. Leslie, DVM; Russell J. Martin, DVM, MPH; Grayson B. Miller, Jr., MD; F. T. Satalowich, DVM, MSPH; Faye E. Sorhage, VMD, MPH. CONSULTANTS TO THE COMMITTEE: James E. Childs, ScD (Centers for Disease Control and Prevention {CDC}); David W. Dreesen, DVM, MPVM; David Hines, PhD (Veterinary Biologics Section, Animal Health Institute); William L. Ingalls, DVM, MS (AVMA Council on Public Health and Regulatory Veterinary Medicine); Robert B. Miller, DVM, MPH (Animal and Plant Health Inspection Service, USDA); Charles E. Rupprecht, VMD, PhD (CDC). ENDORSED BY: American Veterinary Medical Association (AVMA) and the Council of State and Territorial Epidemiologists (CSTE). Address all correspondence to: Suzanne R. Jenkins, VMD, MPH, Virginia State Department of Health, Office of Epidemiology, P.O. Box 2448, Richmond, VA 23218.
Table_1 Note: To print large tables and graphs users may have to change their printer settings to landscape and use a small font size.
Part II: Vaccines Marketed in the United States and NASPHV * Recommendations
===============================================================================================================================================================
Age at
primary Booster Route of
Product name Produced by Marketed by For use in Dosage (mL) vaccination + Recommended innoculation
---------------------------------------------------------------------------------------------------------------------------------------------------------------
A) INACTIVATED
---------------------------------------------------------------------------------------------------------------------------------------------------------------
TRIMUNE Fort Dodge Fort Dodge Dogs 1 3 mos and Triennially IM &
License No. 112 Cats 1 1 yr later Triennially IM
ANNAMUNE Fort Dodge Fort Dodge Dogs 1 3 mos Annually IM
License No. 112 Cats 1 3 mos Annually IM
DURA-RAB 1 ImmunoMed ImmonoMed, Vedco, Inc. Dogs 1 3 mos and Annually IM
License No. 421 Cats 1 3 mos Annually IM
DURA-RAB 3 ImmunoMed ImmunoMed, Vedco, Inc. Dogs 1 3 mos and Triennially IM
License No. 421 Cats 1 1 yr later Triennially IM
RABCINE-3 ImmunoMed Pfizer, Inc. Dogs 1 3 mos and Triennially IM
License No. 421 Cats 1 1 yr later Triennially IM
CHAMPION ImmunoMed AgriLaboratories Dogs 1 3 mos and Triennially IM
PROTECTOR License No. 421 Cats 1 1 yr later Triennially IM
RABIES 3
ENDURALL-P Pfizer, Inc. Pfizer, Inc. Dogs 1 3 mos Annually IM or SQ @
License No. 189 Cats 1 3 mos Annually SQ
RABGUARD-TC Pfizer, Inc. Pfizer, Inc. Dogs 1 3 mos and Triennially IM
License No. 189 Cats 1 1 yr later Triennially IM
Sheep 1 3 mos Annually IM
Cattle 1 3 mos Annually IM
Horses 1 3 mos Annually IM
DEFENSOR Pfizer, Inc. Pfizer, Inc. Dogs 1 3 mos and Triennially IM or SQ
License No. 189 Cats 1 1 yr later Triennially SQ
Sheep 2 3 mos Annually IM
Cattle 2 3 mos Annually IM
RABDOMUN Pfizer, Inc. Mallinckrodt Dogs 1 3 mos and Triennially IM or SQ
License No. 189 Veterinary, Inc. Cats 1 1 yr later Triennially SQ
Sheep 2 3 mos Annually IM
Cattle 2 3 mos Annually IM
RABDOMUN 1 Pfizer, Inc. Mallinckrodr Dogs 1 3 mos Annually IM or SQ
License No. 189 Veterinary, Inc. Cats 1 3 mos Annually IM
SENTRYRAB-1 Pfizer, Inc. Synbiotics Corp. Dogs 1 3 mos Annually IM
License No. 225 Cats 1 3 mos Annually IM
RABVAC 1 Solvay Animal Health, Solvay Animal Health, Dogs 1 3 mos Annually IM or SQ
Inc., License No. 195 Inc. Cats 1 3 mos Annually IM or SQ
and 195A
RABVAC 3 Solvay Animal Health, Solvay Animal Health, Dogs 1 3 mos and Triennially IM or SQ
Inc., License No. 195 Inc. Cats 1 1 yr later Triennially IM or SQ
and 195A Horses 2 3 mos Annually IM
PRORAB-1 Intervet, Inc. Intervet, Inc. Dogs 1 3 mos Annually IM or SQ
License No. 286 Cats 1 3 mos Annually IM or SQ
Sheep 2 3 mos Annually IM
PRORAB-3F Intervet, Inc. Intervet, Inc. Cats 1 3 mos and Triennially IM or SQ
License No. 286 1 yr later
RM IMRAB 3 Rhone Merieux, Inc. Rhone Meriux, Inc. Dogs 1 3 mos and Triennially IM or SQ
License No. 298 Cats 1 1 yr later Triennially IM or SQ
Sheep 2 3 mos and Triennially IM or SQ
1 yr later
Cattle 2 3 mos Annually IM or SQ
Horses 2 3 mos Annually IM or SQ
Ferrets 1 3 mos Annually SQ
RM IMRAB Rhone Merieux, Inc. Rhone Merieux, Inc. Cattle 2 3 mos Annually IM or SQ
BOVINE PLUS License No. 298 Horses 2 3 mos Annually IM or SQ
Sheep 2 3 mos and Triennially IM or SQ
1 yr later
RM IMRAB 1 Rone Merieux, Inc. Rhone Merieux, Inc. Dogs 1 3 mos Annually IM or SQ
License No. 298 Cats 1 3 mos Annually IM or SQ
---------------------------------------------------------------------------------------------------------------------------------------------------------------
B) Combination
---------------------------------------------------------------------------------------------------------------------------------------------------------------
ECLIPSE 3 KP-R Solvay Animal Health, Solvay Animal Health, Cats 1 3 mos Annually IM
Inc., License No. 195 Inc.
and 195A
ECLIPSE 3+ Solvay Animal Health, Solvay Animal Health, Cats 1 3 mos Annually IM or SQ
FeLV/R Inc., License No. 195 Inc.
and 195A
ECLIPSE 4 KP-R Solvay Animal Health, Solvay Animal Health, Cats 1 3 mos Annually IM
Inc., License No. 195 Inc.
and 195A
ECLIPSE 4+ Solvay Animal Health, Solvay Animal Health, Cats 1 3 mos Annually IM or SQ
FeLV/R Inc., License No. 195 Inc.
and 195A
FEL-O-VAX Fort Dodge Fort Dodge Cats 1 3 mos and Triennially IM
PCT-R License No. 112 1 yr later
RM FELINE 4+ Rhone Merieux, Inc. Rhone Merieux, Inc. Cats 1 3 mos and Triennially SQ
IMRAB License No. 298 1 yr later
RM FELINE 3+ Rhone Meriuex, Inc. Rhone Merieux, Inc. Cats 1 3 mos and Triennially SQ
IMRAB License No. 298 1 yr later
RM EQUINE POTOMAVAC+ Rhone Merieux, Inc. Rhone Merieux, Inc. Horses 1 3 mos Annually IM
IMRAB License No. 298
MYSTIQUE II Bayer Corp. Bayer Corp. Horses 1 3 mos Annually IM
License No. 52
---------------------------------------------------------------------------------------------------------------------------------------------------------------
* National Association of State Public Health Veterinarians, Inc.
+ >=3 months of age of revaccinated 1 year later.
& Intramuscularly.
@ Subcutaneously.
===============================================================================================================================================================
Return to top. Disclaimer All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices. **Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.Page converted: 09/19/98 |
|||||||||
This page last reviewed 5/2/01
|